Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03876990
Other study ID # 38RC15.091
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 20, 2019
Est. completion date February 19, 2021

Study information

Verified date October 2021
Source University Hospital, Grenoble
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the clinical benefit of a rapid test for fast diagnosis of bacteremia and fungemia from positive blood cultures in case of sepsis. This assay enables rapid identification of bacteria and fungi and allows to evaluate bacterial resistance to first line antibiotics. The clinical and medico-economic impact of this assay used in addition to the current diagnosis strategy (half of the patients) will be compared to the current diagnostic strategy alone (other half of the patient).


Description:

Bacteremia and fungemia are severe complications, sometimes life-threatening, of every sepsis. During septicemia, every hour matters to start an appropriate antibiotic or antifungal treatment as every hour of delay is associated to higher death rate. The rapid multiplex PCR assay that is evaluated in this study allows to identify in 60 to 90 minutes, the bacteria or fungi that is present in the positive blood culture bottles and to identify resistance markers to first line antibiotics that are used to treat sepsis. This strategy allows quicker adaptation of antibacterial or antifungal treatment based on the species of the bacteria or fungi identified and on the results of the resistance markers compared to current diagnosis strategy of bacteremia or fungemia. This quicker adaptation could lead to improved survival rate, reduced complications of sepsis, reduced hospital stay length and could reduce the use of large spectrum antibiotics.


Recruitment information / eligibility

Status Completed
Enrollment 312
Est. completion date February 19, 2021
Est. primary completion date February 19, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with bacteremia and/or fungemia defined by : 1/ the presence of clinical signs of sepsis; AND 2/ a positive blood culture, i.e. the growth of at least one species of bacteria or micromyces in at least one blood culture vial - Patient Hospitalized at Grenoble University Hospital (only North site) and seen by a physician from the antibiotic stewardship team - First blood culture positive for the patient's sepsis episode - Informed and written consent signed by the patient or his legal representative or the doctor in case of emergency. Exclusion Criteria: - Patients mentioned in the law articles L1121-5 to L1121-8 from French Health Code - Patients hospitalized in palliative care unit - Persons with an estimated survival of less than one month

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Multiplex PCR
Quick adaptation of antibiotic treatment according to the species identified and to the results of the resistance markers present in the multiplex PCR
Current strategy alone
Identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram

Locations

Country Name City State
France Grenoble University Hospital Grenoble

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Grenoble GenMark Diagnostics

Country where clinical trial is conducted

France, 

References & Publications (6)

Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, Shah ND, Mandrekar JN, Patel R. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015 Oct 1;61(7):1071-80. doi: 10.1093/cid/civ447. Epub 2015 Jul 20. — View Citation

Huang TD, Melnik E, Bogaerts P, Evrard S, Glupczynski Y. Evaluation of the ePlex Blood Culture Identification Panels for Detection of Pathogens in Bloodstream Infections. J Clin Microbiol. 2019 Jan 30;57(2). pii: e01597-18. doi: 10.1128/JCM.01597-18. Print 2019 Feb. — View Citation

Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun;34(6):1589-96. — View Citation

Maubon D, Dard C, Garnaud C, Cornet M. Profile of GenMark's ePlex® blood culture identification fungal pathogen panel. Expert Rev Mol Diagn. 2018 Feb;18(2):119-132. doi: 10.1080/14737159.2018.1420476. Epub 2017 Dec 28. — View Citation

Patel TS, Kaakeh R, Nagel JL, Newton DW, Stevenson JG. Cost Analysis of Implementing Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Plus Real-Time Antimicrobial Stewardship Intervention for Bloodstream Infections. J Clin Microbiol. 2016 Dec 28;55(1):60-67. doi: 10.1128/JCM.01452-16. Print 2017 Jan. — View Citation

Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis. Clin Infect Dis. 2017 Jan 1;64(1):15-23. Epub 2016 Sep 26. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Delay from suspicion of sepsis to optimized antibiotic/antifungal treatment Delay between first sampling of blood cultures for sepsis and optimized antibiotic/antifungal treatment. Treatment will be considered optimized if it is active on the bacteria/fungi responsible for sepsis and if it follows current treatment recommendations for the bacteria/fungi identified. Follow up is set to hospital length stay with a maximum of 30 days
Secondary Medical evaluation of the consequences of the innovative strategy compared to current strategy : 30-day mortality The following clinical consequences will be measured and compared in each arm : 30-day mortality Hospital length stay with a maximum of 30 days
Secondary Medical evaluation of the consequences of the innovative strategy compared to current strategy : complication rate The following clinical consequences will be measured and compared in each arm : complication rate (ICU admission or length of stay, antibiotic/antifungal treatment toxicity rate, recurrence of sepsis within 30 days, re-admission to hospital within 30 days) Hospital length stay with a maximum of 30 days
Secondary Medical evaluation of the consequences of the innovative strategy compared to current strategy : length of hospital stay The following clinical consequences will be measured and compared in each arm : length of hospital stay Hospital length stay with a maximum of 30 days
Secondary Medical evaluation of the consequences of the innovative strategy compared to current strategy : antibiotic treatment duration The following clinical consequences will be measured and compared in each arm : treatment duration for antibiotics with high impact on the commensal flora (i.e. : carbapenems) or with high toxicity (i.e. : vancomycin) Hospital length stay with a maximum of 30 days
Secondary Medical evaluation of the consequences of the innovative strategy compared to current strategy : delay of antibiotic/antifungal treatment modification at several time points The following clinical consequences will be measured and compared in each arm : delay of antibiotic/antifungal treatment modification at several time points (after the result of the Gram stain, after the results of the multiplex PCR, after the results of the identification of the bacteria/fungi and after the results of antibiotic/antifungal treatment susceptibility). Hospital length stay with a maximum of 30 days
Secondary Medical evaluation of the consequences of the innovative strategy compared to current strategy : rate of antibiotic/antifungal treatment modification at several time points The following clinical consequences will be measured and compared in each arm : rate of antibiotic/antifungal treatment modification at several time points (after the result of the Gram stain, after the results of the multiplex PCR, after the results of the identification of the bacteria/fungi and after the results of antibiotic/antifungal treatment susceptibility). Hospital length stay with a maximum of 30 days
Secondary Economic evaluation of the hospitalization costs of the innovative strategy compared to current strategy Hospitalization costs will be measured Hospital length stay with a maximum of 30 days
Secondary Economic evaluation of the treatments costs of the innovative strategy compared to current strategy Anti-infectious treatment costs will be measured Hospital length stay with a maximum of 30 days
Secondary Economic evaluation of the costs of the innovative compared to current strategy Costs of the innovative assay (reagents and device) will be measured Hospital length stay with a maximum of 30 days
Secondary Economic evaluation of the medical imaging costs of the innovative strategy compared to current strategy Medical imaging costs will be measured Hospital length stay with a maximum of 30 days
Secondary Economic impact of the introduction of the innovative strategy for Grenoble University Hospital Measurement and evaluation of the economic impact of the innovative strategy on the budget of Grenoble University Hospital, on the target population, for a period of one year. Extrapolation of the costs for a one year period
See also
  Status Clinical Trial Phase
Completed NCT00177788 - Voriconazole as Prophylaxis for Liver Transplant Recipients N/A
Completed NCT00027248 - Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections Phase 3
Completed NCT01359891 - Clinical Evaluation of Novel Biomarkers in Patients With Septicemia
Completed NCT00794703 - A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections Phase 3
Completed NCT00001937 - Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Phase 3
Recruiting NCT01260974 - Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients Phase 2
Recruiting NCT04368559 - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 3
Completed NCT01236261 - Prospective Population Study on Candidemia in Spain N/A
Active, not recruiting NCT02743585 - Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT) N/A
Completed NCT02734862 - CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Phase 2
Completed NCT02719769 - Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture N/A
Completed NCT01450358 - Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture. Phase 4
Completed NCT00841971 - Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients Phase 4
Completed NCT01898208 - Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures N/A
Terminated NCT00806351 - An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System Phase 3
Terminated NCT00805740 - An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida Phase 3
Unknown status NCT00460330 - Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT N/A
Completed NCT00001810 - An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Phase 3